Medicare Enrolled
Dr. Dhiman Basu, MD
Internal Medicine · Colleyville, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Basu from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Basu?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Basu
Dr. Dhiman Basu is an internal medicine specialist in Colleyville, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Basu performed 72,122 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Basu received a total of $1,759,063 from 72 pharmaceutical and/or device companies across 4466 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Basu is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 1% volume in TX
$1,759,063 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗72,122
Medicare services
Top 1% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
54,800 | $4 | $13 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
8,700 | $30 | $96 |
| Denosumab injection (Prolia/Xgeva) | 4,260 | $17 | $53 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
2,560 | $26 | $86 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
836 | $91 | $270 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
447 | $53 | $189 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
252 | $96 | $345 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
118 | $1 | $15 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
96 | $22 | $110 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
30 | $62 | $233 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
23 | $118 | $415 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
16.0% high complexity
82.8% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,759,063
Total received (2018-2024)
Avg $251,295/year across 7 years
Top 0% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
4,466
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$294,916
2023
$309,627
2022
$263,943
2021
$231,649
2020
$119,148
2019
$312,538
2018
$227,242
Payments by company (2024)
Amgen Inc.
$63,002
ANI Pharmaceuticals, Inc.
$40,113
UCB, Inc.
$33,694
Alexion Pharmaceuticals, Inc.
$29,198
Janssen Biotech, Inc.
$26,668
Aurinia Pharma U.S., Inc.
$18,189
AstraZeneca Pharmaceuticals LP
$16,385
Kyowa Kirin, Inc.
$14,617
ABBVIE INC.
$14,263
GENZYME CORPORATION
$13,091
Mallinckrodt Hospital Products Inc.
$8,968
GlaxoSmithKline, LLC.
$6,886
Novartis Pharmaceuticals Corporation
$6,541
E.R. Squibb & Sons, L.L.C.
$1,007
UCB SA
$920
PFIZER INC.
$274
Lilly USA, LLC
$191
Octapharma USA, Inc.
$188
Organon Llc
$161
AstraZeneca UK Limited
$135
Alnylam Pharmaceuticals Inc.
$103
SANOFI-AVENTIS U.S. LLC
$80
Janssen Scientific Affairs, LLC
$58
Kiniksa Pharmaceuticals International, plc
$54
Boehringer Ingelheim Pharmaceuticals, Inc.
$46
Radius Health, Inc.
$26
Pacira Pharmaceuticals Incorporated
$26
Bayer Healthcare Pharmaceuticals Inc.
$18
Genentech USA, Inc.
$13
Top 3 companies account for 46.4% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$245,719
Lilly USA, LLC
$149,001
Novartis Pharmaceuticals Corporation
$126,539
Aurinia Pharma U.S., Inc.
$114,313
AstraZeneca Pharmaceuticals LP
$108,827
Mallinckrodt Hospital Products Inc.
$104,731
Mallinckrodt Enterprises LLC
$95,535
Janssen Scientific Affairs, LLC
$83,149
GlaxoSmithKline, LLC.
$82,828
Alexion Pharmaceuticals, Inc.
$74,488
UCB, Inc.
$68,695
GENZYME CORPORATION
$57,840
ANI Pharmaceuticals, Inc.
$57,133
Janssen Biotech, Inc.
$53,220
AbbVie, Inc.
$42,189
ABBVIE INC.
$39,940
PFIZER INC.
$37,598
Celgene Corporation
$35,565
AbbVie Inc.
$33,126
Ironwood Pharmaceuticals, Inc
$25,995
Mallinckrodt LLC
$21,391
Genentech USA, Inc.
$18,898
Kyowa Kirin, Inc.
$14,789
Sandoz Inc.
$10,889
Horizon Therapeutics plc
$9,617
Exeltis, USA Inc.
$8,886
E.R. Squibb & Sons, L.L.C.
$7,511
Gilead Sciences, Inc.
$5,253
UCB SA
$5,012
Regeneron Healthcare Solutions, Inc.
$4,508
Pfizer Inc.
$3,597
Octapharma USA, Inc.
$3,085
Regeneron Pharmaceuticals, Inc.
$3,030
Horizon Pharma plc
$1,931
SANOFI-AVENTIS U.S. LLC
$914
Radius Health, Inc.
$582
Genentech, Inc.
$358
Boehringer Ingelheim Pharmaceuticals, Inc.
$287
Antares Pharma, Inc.
$193
Organon LLC
$187
Takeda Pharmaceuticals U.S.A., Inc.
$168
Arbor Pharmaceuticals, Inc.
$162
Organon Llc
$161
ARBOR PHARMACEUTICALS, INC.
$138
AstraZeneca UK Limited
$135
Sobi, Inc
$103
Alnylam Pharmaceuticals Inc.
$103
Actelion Pharmaceuticals US, Inc.
$69
Hikma Pharmaceuticals USA
$60
Kiniksa Pharmaceuticals International, plc
$54
Ultragenyx Pharmaceutical Inc.
$53
Pacira Pharmaceuticals Incorporated
$53
Zyla Life Sciences
$50
Kiniksa Pharmaceuticals, Ltd.
$43
Bioventus LLC
$31
Flexion Therapeutics, Inc.
$30
MEDEXUS PHARMA, INC.
$28
Purdue Pharma L.P.
$28
MEDAC PHARMA, INC.
$27
Mission Pharmacal Company
$25
Ferring Pharmaceuticals Inc.
$23
Eisai Inc.
$21
DePuy Synthes Sales Inc.
$21
Bayer Healthcare Pharmaceuticals Inc.
$18
West-Ward Pharmaceuticals
$18
Fresenius Kabi USA, LLC
$16
Assertio Therapeutics, Inc.
$14
Celltrion USA Inc.
$14
SI-BONE, Inc.
$13
Vertical Pharmaceuticals, LLC
$13
Azurity Pharmaceuticals, Inc.
$13
ASSERTIO THERAPEUTICS, Inc.
$12
Top 3 companies account for 29.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · Binosto · COSENTYX · CYLTEZO · Cambia · Cimzia · Crysvita · DUZALLO · Dayvigo · ERELZI · EUFLEXXA · EVENITY · EVUSHELD · Enbrel · FORTEO · GELSYN-3 · GIVLAARI · HADLIMA · HUMIRA · HYQVIA · Horizant · Humira · IDACIO · ILARIS · Iovera · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kerendia · Kineret · LINZESS · LORZONE · LUPKYNIS · LYRICA · Mitigare · NEXPLANON · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OLUMIANT · ORENCIA · ORTHOVISC · OTREXUP · Otezla · Otrexup · PANZYGA · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYMPROIC · Strensiq · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · Tavneos · Tymlos · ULTOMIRIS · UPTRAVI · Uloric · XELJANZ · XYOSTED · YUFLYMA · ZIPSOR · ZORVOLEX · Zilretta · iFuse Implant
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
2,347
County median income
$81,905
Nearest hospital to ZIP centroid (approximate)
SAINT CAMILLUS MEDICAL CENTER
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Basu is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Basu experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Basu performed 54,800 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Basu receive payments from pharmaceutical companies?
Yes. Dr. Basu received a total of $1,759,063 from 72 companies across 4,466 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Basu's costs compare to other internal medicine physicians in Colleyville?
Dr. Basu's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Basu) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Colleyville
Browse internal medicine physicians in Colleyville ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology